It plays a central role in the transformation and layout of medical services for major shareholders. The core model of transformation is based on Peking University Medical School to form a hospital network through self-construction, mergers and acquisitions, and trusteeship, etc., to build a whole medical service industry chain. The main role of the company in the layout: 1. As the only medical capital securitization platform under the majority shareholders, it has the mission of integrating the value-added and financing of medical resources; 2. As the main body in the medical service industry chain, it controls the pharmaceutical R&D, production and distribution links, and collaborates with other players. At present, the subsidiary Beijing Medical Pharmaceutical has signed a cooperation agreement with the People's Hospital, marking the official start of connecting the distribution sector with hospital resources. Drawing on the experience of Chang Gung Hospital, it is hoped to exert a catfish effect in public hospital reform. Currently, various problems in China's medical industry are forcing medical reform, and the policy strongly supports social capital to carry out medical treatment. Peking University Medical Group has taken advantage of new medical reform opportunities to vigorously integrate hospital resources and reserve momentum for the entire medical service industry chain. At the same time, drawing on Chang Gung Hospital's empirical model, the enterprise management concept was introduced into hospital management, and relying on Peking University Medical School to export management, talent, and technology to mergers and acquisitions and self-built hospitals to improve the quality of hospital resources. It is also expected to exert a catfish effect in medical reform. The first step in the transformation of medical services - the layout of the entire oncology specialty industry chain has basically been completed. The company began developing oncological drugs in the early stages, and is currently collaborating with Fangzheng Pharmaceutical Research Institute to develop new drugs such as pretin disodium phosphate. After the acquisition of Integrated Medicine, the layout of cancer diagnosis services was completed. If oncology specialist hospitals are acquired from property rights and managed through the experience of Peking University Cancer Hospital, it is possible to create an entire medical service industry chain under the “Peking University Oncology” brand. Profit forecasting and valuation. Assuming 15 years of integrated health care, the company's net profit for 14-16 is predicted to be 87.21 million, 150 million, and 280 million yuan, and EPS of 0.15, 0.21, and 0.38 yuan. For the first time, it is given a “buy” rating, and the target price is 28 yuan.